Could FTC scrutiny of the Roche-Spark merger scuttle future pharma deals? Analysts are fretting

FiercePharma | August 02, 2019

When Roche delayed its planned 4.8 billion dollars purchase of gene therapy developer Spark Therapeutics for the fifth time earlier this week, citing the Federal Trade Commissions FTCs review of the deal, one burning question emerged among pharma watchers- What the heck is the FTCs problem? Shortly thereafter, another troubling question bubbled up- If the FTC is going to be this nitpicky about one giant pharma company’s effort to buy a relatively small player, could that end up scuttling future deals? Bloomberg surveyed nine firms that specialize in mergers and acquisitions, and six of them said they're worried the FTC has changed its approach to reviewing deals. A similar majority said the change—which has yet to be fully understood—could give future dealmakers second thoughts. “You have to start wondering if this scrutiny will slow down or prohibit these kinds of deals, which would be a huge deal for the sector,” said Brad Loncar, CEO of Loncar Investments, in an interviewwith Bloomberg.

Spotlight

DRUG DEVELOPMENT HAS BEEN DESCRIBED AS THE PROCESS OF OBTAINING THE INFORMATION YOU WANT TO BE INCLUDED ON YOUR DRUG’S PRESCRIBING INFORMATION. AT THE BOTTOM TIP IS THE DRUG ITSELF, AND ACROSS THE BROAD TOP IS THE PRESCRIBING INFORMATION. EVERYTHING IN BETWEEN IS DRUG DEVELOPMENT.

Spotlight

DRUG DEVELOPMENT HAS BEEN DESCRIBED AS THE PROCESS OF OBTAINING THE INFORMATION YOU WANT TO BE INCLUDED ON YOUR DRUG’S PRESCRIBING INFORMATION. AT THE BOTTOM TIP IS THE DRUG ITSELF, AND ACROSS THE BROAD TOP IS THE PRESCRIBING INFORMATION. EVERYTHING IN BETWEEN IS DRUG DEVELOPMENT.

Related News

RESEARCH

UConn startup DIANT bags license for continuous nanoparticle manufacturing tech

UConn | November 20, 2020

Consistent assembling has just begun to override customary group handling in the domain of tablet creation. The following region due for an assembling update? Nanoparticle drug conveyance frameworks, one startup thinks—and it's currently prepared to pitch its foundation to drugmakers. The University of Connecticut as of late authorized its ceaseless nanoparticle fabricating innovation to DIANT Pharma, a startup helped to establish by the stage's designers Antonio Costa, Ph.D., and Diane Burgess, Ph.D. The high-throughput framework can possibly spare tidy up room space, bring down the quantity of preparing steps and diminish the quantity of bunches created every year. Since the stage is persistent, it should empower makers to hop in the event that anything turns out badly, redirecting or eliminating just a little bit of the item instead of rejecting a whole group, Costa, CEO at DIANT and partner research teacher at UConn, said in a meeting.

Read More

PHARMACY MARKET

Crosscope Inc Allies with Waleed Pharmacy for Pathology Solutions in Oman

Crosscope Inc. | April 11, 2022

Crosscope Inc. teams up with Waleed Pharmacy & Stores LLC. The latter focuses on fetching healthcare, hospital, and pharmaceutical solutions to the Sultanate of Oman, whereas Crosscope provides AI-enabled digital pathology software. Both have signed Memorandum of Understanding to facilitate a makeover in the Histopathology arena that uses Crosscope’s AI-enabled digital pathology platform. Moreover, both aim to bring pioneering technical solutions to Oman that allows commercial use that will reduce the country's cancer load, which is one of the chief health concern around the world. Oman is facing severity in terms of Cancer spread, as per World Health Organization. Crosscope Dx comes with an integrated workflow that works on the platform of vendor-agnostic digital pathology, which comes with comprehensive solutions for digital pathology. Moreover, Crosscope presents features such as advanced workflow, cohesive and easy to follow workflow solutions and open and scalable architecture designed for pathologists to decrease their workload, lessen the reversal time, guarantee quicker diagnosis, and a reduced outbreak of the disease in the region. Because of this partnership, Waleed Pharmacy will be Crosscope's official representative in Oman. Both firms plan to provide cancer diagnosis service providers with state-of-the-art comprehensive Digital Pathology Platforms, AI, and ML capabilities. They'll also look into all available options for collaboration, collaborating and using each other's knowledge, network, and know-how to improve the region's cancer diagnostics environment. "We are delighted to join forces with the Waleed Pharmacy group. Waleed Pharmacy's experienced team has a proven track record of delivering and deploying healthcare IT solutions in the Oman region and represents a perfect partner for Crosscope. By teaming up, we are confident that we have created the synergies to boost the development and commercialization of our digital pathology workflows," Dr. Jayendra Shinde, CEO of Crosscope Crosscope may collaborate with the region's most respected key opinion leaders in prestigious hospitals, clinical institutions, diagnostic chains, R&D labs, research organizations, pharma companies, and other organizations in the related space where the company's products provide clinical value to users.

Read More

PHARMA TECH

Veeva Development Cloud Simplifies Drug Development in the Industry

Veeva Systems | May 21, 2021

A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems in an industrywide shift to streamline drug development. quite 650 companies use Veeva Development Cloud applications today, and quite 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams. Veeva Development Cloud brings together suites of unified applications for clinical, regulatory, quality, and safety on one cloud platform, eliminating organizational siloes. quite 350 companies are accelerating trial execution with Vault Clinical applications, quite 250 are streamlining regulatory processes with Vault RIM, quite 350 are unifying quality management with Vault Quality, and quite 35 are improving pharmacovigilance with Vault Safety. Vault Connections in Veeva Development Cloud drive cross-functional business processes across the merchandise lifecycle. For instance, Connections enable companies to compile clinical operations and regulatory for faster submissions; quality and regulatory for simplified change control and variation management; and clinical data and operations for real-time visibility into patient enrollment. "We're dedicated to bringing innovations to plug that help the industry accelerate drug development," said Jim Reilly, vice chairman of Veeva Vault R&D. "Veeva Development Cloud is enabling customers to enhance collaboration across teams and speed the delivery of treatments to patients." About Veeva Systems Veeva is that the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves quite 975 customers, starting from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and therefore the industries it serves.

Read More